Physician profile
Katherine E Lampert
NPI 1932552262
$14,968.82
in general payments reported to CMS, 2019-2025
27 companies · $4,422 in 2025
The $4,422 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,466 · 2023: $3,344 · 2024: $5,737 · 2025: $4,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,064.28 |
| Education | $438.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,840.62 | 2022-2025 | |
| Janssen Biotech, INC. | $2,167.00 | 2022-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $1,518.49 | 2022-2025 | |
| Ucb, INC. | $920.99 | 2022-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $802.81 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $799.01 | 2022-2025 | Ilumya, Blu-U, Odomzo |
| Incyte Corporation | $789.19 | 2022-2025 | Opzelura, Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $695.92 | 2023-2025 | Siliq, Cabtreo, Jublia |
| E.R. Squibb & Sons, L.L.C. | $629.86 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $519.09 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $403.40 | 2022-2025 | |
| Leo Pharma INC. | $400.89 | 2022-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $331.15 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $266.92 | 2023-2024 | Vtama |
| Amgen INC. | $145.55 | 2022-2024 | Otezla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.80 | 2022-2024 | Cyltezo, Spevigo |
| Organon LLC | $103.07 | 2023-2025 | Hadlima |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $78.38 | 2022-2025 | Valchlor |
| Biofrontera INC. | $65.87 | 2022 | |
| Kyowa Kirin, INC. | $65.40 | 2022-2024 | Poteligeo |
| Pfizer INC. | $55.41 | 2024-2025 | |
| Galderma Laboratories, L.P. | $49.86 | 2024-2025 | Nemluvio, Aklief |
| Paratek Pharmaceuticals, INC. | $45.95 | 2022-2024 | Nuzyra |
| Chiesi USA, INC. | $26.20 | 2024 | Filsuvez |
| Sandoz INC. | $20.48 | 2023 | Hyrimoz |
| Mission Pharmacal Company | $14.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Lampert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.